Our Sleep device can enhance clinical practice across all medical specialties. Prior to the onset of chronic disease, symptoms may be present, and prior to symptoms, there are reflections of changes in ANS regulation that are not obvious. The sleep period, on average represents one-third of a person´s life, and getting sufficient good quality sleep at the right circadian times is vital for good health and well-being as during sleep, muscles and tissues are rebuilt, neuroendocrine and metabolic functions are regulated, information collected during the waking hours are reorganized and consolidated for learning and memory, and the immune system is strengthened. These benefits of sleep can only happen when sleep is dominated by parasympathetic activity (good quality sleep). The Sleep output clearly distinguishes between parasympathetic and sympathetic dominance and presents the output as 'Stable' and 'Unstable' sleep reflecting sleep health.
Our device is a Revolutionary Approach to Screen, Diagnose and Manage Sleep Health in Children & Adults to:
Measure Sleep Quality
Measure Sleep Duration
Evaluate Sleep Disorders
Diagnose Sleep Apnea
-Obstructive and Central
The Sleep System is based on coupling heart rate variability (HRV) and respiration data collected during sleep, biosignals both highly influenced by the ANS (sympathetic and parasympathetic influence). Observing the synchronization between the cardiovascular- and respiratory systems (coupling) during sleep when there are minimum environmental stimuli that can affect the ANS as happens during wake, allows for measures of sleep and sleep staging. SpO2 data is used with CPC data to calculate the SleepImage Apnea-Hypopnea Index (sAHI) and the SleepImage Respiratory Disturbance Index (sRDI). The data is automatically calculated, and the output is presented through easy-to-understand biomarkers, that are displayed with expected normative thresholds and color-coded results for each biomarker. The SleepImage FDA-clearance states that (1) SleepImage establishes Sleep Quality based on the Sleep Quality Index (SQI), a summary biomarker of sleep health cleared as a unit of measure, presented on a scale of 0 100. The SQI has demonstrated a direct relationship with health outcomes in clinical studies, (2) the SleepImage Apnea-Hypopnea Index (sAHI) has been clinically validated and FDA-cleared for children, adolescents and adults for diagnosis and management of Sleep Disordered Breathing (SDB).
OSA was Found in Over 70% of Type 2 Diabetics in a Meta-Analysis, Therefore Clinicians Should Consider Treatments for Patients.
Symptoms related to sleep or screening for sleep apnea have been overlooked by cardiac, diabetic, pulmonary, and general medicine clinics despite recommendations for screening by several societies. Data has been in the scientific literature for several years, indicating the associations of OSA with almost any disease like glaucoma, end-stage renal disease, chronic obstructive pulmonary disease, polycystic ovarian syndrome, metabolic syndrome, cardiovascular disease, stroke, depression, obesity, and DM. OSA has also be identified in non-obese patients and children with enlarged tonsils and adenoids. Moreover, the treatment has led to improvements in the underlying condition [36-38]. Early diagnosis and treatment of OSA will help in preventing the increased morbidity and mortality associated with those conditions. Studies have shown that improvement in ejection fraction, carotid intimal thickening and benefits in coronary artery disease, maintenance of sinus rhythm from A-Fib after cardioversion, and improvement in insulin resistance while untreated OSA is associated with an increased risk of death.
Early Diagnosis and Treatment of OSA can Significantly Reduce Morbidity and Mortality Risks